Compare VRCA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | ECOR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | 83 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 85.6M |
| IPO Year | 2018 | 2018 |
| Metric | VRCA | ECOR |
|---|---|---|
| Price | $5.39 | $9.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $17.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 102.4K | 99.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,577,000.00 | $32,032,000.00 |
| Revenue This Year | N/A | $33.60 |
| Revenue Next Year | $94.44 | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 370.22 | 27.20 |
| 52 Week Low | $3.28 | $4.41 |
| 52 Week High | $9.82 | $10.95 |
| Indicator | VRCA | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 52.02 |
| Support Level | $4.52 | $8.55 |
| Resistance Level | $6.22 | $10.34 |
| Average True Range (ATR) | 0.43 | 0.86 |
| MACD | 0.08 | -0.14 |
| Stochastic Oscillator | 49.60 | 18.55 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.